AAV8基因治疗与饮食因素共同诱发X连锁肌管肌病小鼠胆汁淤积性肝病
在X连锁肌管肌病(XLMTM)小鼠模型中,Mtmt1缺失与断奶后饮食环境相互作用,导致肝功能障碍,模拟了患者接受AAV8-MTM1基因治疗后出现的致命性肝损伤。脂质纳米颗粒MTM1基因替代可预防关键肝脏病理异常,为建模AAV相关毒性提供了框架。
要点
- Mtmt1敲除小鼠喂食纯化成分饲料后出现转氨酶升高、胆汁酸组成改变和胆汁淤积组织学特征。
- MTM1维持肝细胞结构和胆盐输出泵定位,肝特异性Mtmt1缺失可重现部分特征。
- 脂质纳米颗粒MTM1基因替代可预防全局敲除小鼠的关键肝脏病理异常。
核心结论
- Mtmt1缺失与断奶后环境相互作用,通过多因素机制诱发XLMTM小鼠胆汁淤积性肝损伤。
- AAV8基因治疗在饮食致敏小鼠中增加胆汁淤积易感性,并可在野生型小鼠中诱导肝损伤。
研究设计与样本
- 研究使用XLMTM小鼠模型(Mtmt1敲除小鼠),设置不同饮食(纯化成分饲料)和基因治疗干预(AAV8驱动基因治疗、脂质纳米颗粒MTM1基因替代)。
- 研究包括全局敲除小鼠和肝特异性Mtmt1缺失小鼠,以评估肝脏自主性作用。
主要发现
- Mtmt1敲除小鼠喂食纯化成分饲料后出现血浆转氨酶升高、胆汁酸组成改变和胆汁淤积组织学特征。
- MTM1在维持肝细胞结构和胆盐输出泵定位中起作用,肝特异性Mtmt1缺失重现许多特征。
- AAV8基因治疗在饮食致敏的全局敲除小鼠中增加胆汁淤积易感性,并在野生型小鼠中诱导肝损伤。
- 脂质纳米颗粒MTM1基因替代可预防全局敲除小鼠关键肝脏病理异常的发展。
临床怎么用
- 提示在XLMTM基因治疗中需关注饮食等环境因素对肝毒性的潜在影响。
- 脂质纳米颗粒基因替代可能作为减轻肝损伤的策略,但需进一步临床验证。
局限性
- 研究基于小鼠模型,结果外推到人类需谨慎。
- AAV8肝损伤机制尚未完全阐明,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adeno-associated virus (AAV)-mediated liver injury is the primary off-target toxicity observed with viral gene therapy. Understanding of the underlying mechanisms has been hindered by the fact that murine studies poorly model AAV toxicity. The X-linked myotubular myopathy (XLMTM) gene therapy program epitomizes this therapeutic discordance, because a subset of participants treated with AAV8-driven myotubularin (MTM1) gene replacement developed fatal liver injury that was not predicted by preclinical models. Here, we investigated a multihit hypothesis whereby loss of Mtm1 interacts with the postweaning environment to precipitate liver injury in XLMTM mouse models. Mtm1 knockout (KO) mice fed purified ingredient diets manifested liver dysfunction that mirrored patient clinical presentations, including elevated plasma transaminases, altered bile acid composition, and histological features of cholestasis. We further demonstrated a role for MTM1 in maintaining hepatocyte structure and localization of the bile salt export pump. Liver-specific deletion of Mtm1 recapitulated many of these features, supporting a liver-autonomous role for Mtm1. Treatment of diet-sensitized mice with AAV8-driven gene therapy increased the susceptibility of cholestasis in global KO mice and induced liver injury in wild-type mice. Last, as a proof of concept, we treated global KO mice with lipid nanoparticle MTM1 gene replacement, which prevented development of key histopathological liver abnormalities. These findings provide critical insights into the environmental precipitants and molecular mechanisms of liver dysfunction in XLMTM and the adverse events seen in viral gene therapy studies and more broadly offer a framework to model AAV-associated toxicity and identify potential therapeutic interventions.
引用
- Pannia E, Simonian R, Sabha N, et al. AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy. Sci Transl Med. 2026. PMID: 41706871. doi:10.1126/scitranslmed.adr1483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。